A new study finds some COVID-19 vaccine skin reactions, including a measles-like rash and shingles, are rare, and thankfully brief, side effects.
Author: Elizabeth Weise, USA TODAY
Anti-Asian hashtags soared after Donald Trump first tied COVID-19 to China on Twitter, study shows
The week after then-President Donald Trump first used the #chinesevirus hashtag, the number of people using the hashtag increased more than tenfold.
What if you had your choice of COVID-19 vaccine? Differences are small, but they do exist
If you get the choice, which COVID-19 vaccine should you choose? For now, any one you can get. But supply is growing, and there are differences.
America could soon be swimming in COVID-19 vaccine. The shift from scarcity to surplus could bring its own problems.
The abundance of vaccine will become a stagnating surplus that threatens to undermine the nation’s ability to move beyond the pandemic, experts say.
Want to hug again? Go to church? ‘It’s up to you,’ Ad Council says in $500M campaign to promote COVID-19 vaccines
The ads are aimed at the 40% of Americans who haven’t yet made up their minds about getting vaccinated against COVID-19.
‘Somewhere in there, the vaccine got overpromised’: How the COVID-19 vaccination process turned chaotic and confusing
A lack of transparency, coupled with a short supply, has complicated America’s COVID-19 vaccination efforts. Are things getting better now?
There’s not a ‘giant national campaign’ for COVID-19 vaccine education. Why? Experts say there’s a better way.
Communication experts say targeted messaging is the right approach to address COVID-19 vaccine hesitancy and raise awareness of public health efforts.
‘This is fantastic’: Mass vaccination clinics to play key role in ending COVID-19 pandemic
High-volume vaccination centers will become common in US as the Biden administration seeks to vaccinate 1.5 million a day.
Moderna coronavirus vaccines are on the way, will start arriving in states Monday
Moderna coronavirus vaccine deliveries should begin to arrive across the nation on Monday as shipments of Pfizer-BioNTech vaccine continue.
States were left scrambling after finding out they’d get 20-40% less vaccine than they expected. Here’s why.
After some confusion, the source of the problem was clarified Friday night: States were given estimates based on vaccine doses produced, not those that had been OK’d.